Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma

Current therapeutic approaches to asthma have had limited impact on the cli nical management and resolution of this disorder. By using a novel vaccine strategy targeting the inflammatory cytokine IL-5, we have ameliorated hall mark features of asthma in mouse models. Delivery of a DNA vaccine encoding murine IL-5 modified to contain a promiscuous foreign Th epitope bypasses B cell tolerance to IL-5 and induces neutralizing polyclonal anti-IL-5 Abs. Active vaccination against IL-5 reduces airways inflammation and prevents the development of eosinophilia, both hallmark features of asthma in animal models and humans. The reduced numbers of inflammatory T cells and eosinop hils in the lung also result in a marked reduction of Th2 cytokine levels. Th-modified IL-5 DNA vaccination reduces the expression of IL-5 and IL-4 by similar to 50% in the airways of allergen-challenged mice. Most importantl y, Th-modified IL-5 DNA vaccination restores normal bronchial hyperresponsi veness to beta -methacholine. Active vaccination against IL-5 reduces key p athological events associated with asthma, such as Th2 cytokine production, airways inflammation, and hyperresponsiveness, and thus represents a novel therapeutic approach for the treatment of asthma and other allergic condit ions.